{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T22:02:12Z","timestamp":1722808932172},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1097\/fpc.0000000000000263","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T13:25:31Z","timestamp":1483709131000},"page":"101-111","source":"Crossref","is-referenced-by-count":6,"title":["Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202"],"prefix":"10.1097","volume":"27","author":[{"given":"Anurag","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shefali S.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Pendergrass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Daar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Venuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marylyn D.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210213","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"R2-3-20210213","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/466531","article-title":"Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia","volume":"192","author":"Rotger","year":"2005","journal-title":"J Infect Dis"},{"key":"R3-3-20210213","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/pgs.13.190","article-title":"Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics","volume":"15","author":"Chen","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R4-3-20210213","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants","volume":"22","author":"Holzinger","year":"2012","journal-title":"Pharmacogenet Genom"},{"key":"R6-3-20210213","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FPC.0b013e328336eee4","article-title":"ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir","volume":"20","author":"Lubomirov","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R7-3-20210213","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"key":"R8-3-20210213","doi-asserted-by":"crossref","first-page":"e1003087","DOI":"10.1371\/journal.pgen.1003087","article-title":"Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network","volume":"9","author":"Pendergrass","year":"2013","journal-title":"PLoS Genet"},{"key":"R9-3-20210213","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/gepi.20589","article-title":"The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery","volume":"35","author":"Pendergrass","year":"2011","journal-title":"Genet Epidemiol"},{"key":"R10-3-20210213","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000381851","article-title":"Phenome-wide association studies: embracing complexity for discovery","volume":"79","author":"Pendergrass","year":"2015","journal-title":"Hum Hered"},{"key":"R11-3-20210213","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s40142-015-0067-9","article-title":"Phenome-wide association studies: leveraging comprehensive phenotypic and genotypic data for discovery","volume":"3","author":"Pendergrass","year":"2015","journal-title":"Curr Genet Med Rep"},{"key":"R12-3-20210213","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrg.2015.36","article-title":"Unravelling the human genome-phenome relationship using phenome-wide association studies","volume":"17","author":"Bush","year":"2016","journal-title":"Nat Rev Genet"},{"key":"R13-3-20210213","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bib\/bbv050","article-title":"The detection and characterization of pleiotropy: discovery, progress, and promise","volume":"17","author":"Tyler","year":"2016","journal-title":"Brief Bioinform"},{"key":"R14-3-20210213","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrg3461","article-title":"Pleiotropy in complex traits: challenges and strategies","volume":"14","author":"Solovieff","year":"2013","journal-title":"Nat Rev Genet"},{"key":"R15-3-20210213","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/QAD.0b013e3283427e05","article-title":"Paradoxically elevated efavirenz concentrations in HIV\/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy","volume":"25","author":"Kwara","year":"2011","journal-title":"AIDS"},{"key":"R16-3-20210213","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1097\/QAD.0b013e328360dbb4","article-title":"Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype","volume":"27","author":"McIlleron","year":"2013","journal-title":"AIDS"},{"key":"R17-3-20210213","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/cid\/civ155","article-title":"Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study","volume":"60","author":"Luetkemeyer","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R18-3-20210213","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"R19-3-20210213","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/FPC.0000000000000238","article-title":"Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race","volume":"26","author":"Leger","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"R20-3-20210213","doi-asserted-by":"crossref","first-page":"ofv085","DOI":"10.1093\/ofid\/ofv085","article-title":"Screening for UGT1A1 genotype in study A5257 would have markedly reduced premature discontinuation of atazanavir for hyperbilirubinemia","volume":"2","author":"Vardhanabhuti","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"R21-3-20210213","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"R22-3-20210213","doi-asserted-by":"crossref","first-page":"ofu113","DOI":"10.1093\/ofid\/ofu113","article-title":"Phenome-wide associations study (PheWAS) relating pre-treatment laboratory parameters with human genetic variants in AIDS clinical trials group protocols","volume":"2","author":"Moore","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"R24-3-20210213","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir\u2013lamivudine versus tenofovir\u2013emtricitabine for initial HIV-1 therapy","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"R25-3-20210213","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1","volume":"154","author":"Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"R26-3-20210213","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/QAD.0b013e3282f7cb76","article-title":"CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection","volume":"22","author":"Baker","year":"2008","journal-title":"AIDS"},{"key":"R27-3-20210213","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAD.0b013e32834f32f8","article-title":"Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort","volume":"26","author":"van Lelyveld","year":"2012","journal-title":"AIDS"},{"key":"R28-3-20210213","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/QAD.0b013e32832e9b78","article-title":"Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy","volume":"23","author":"Marin","year":"2009","journal-title":"AIDS"},{"key":"R29-3-20210213","first-page":"541","article-title":"Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases","volume":"48","author":"Baker","year":"2008","journal-title":"JAIDS"},{"key":"R30-3-20210213","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","article-title":"Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment","volume":"210","author":"Tenorio","year":"2014","journal-title":"J Infect Dis"},{"key":"R31-3-20210213","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"R32-3-20210213","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"R33-3-20210213","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"R34-3-20210213","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"Gutierrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R35-3-20210213","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-6405-7-32","article-title":"Presence of the CYP2B6 516G> T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients","volume":"7","author":"Gounden","year":"2010","journal-title":"AIDS Res Ther"},{"key":"R36-3-20210213","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals","volume":"143","author":"Clifford","year":"2005","journal-title":"Ann Intern Med"},{"key":"R37-3-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genom"},{"key":"R38-3-20210213","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"R39-3-20210213","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1086\/380791","article-title":"Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz","volume":"38","author":"Gallego","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R40-3-20210213","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/cir131","article-title":"Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy","volume":"52","author":"Gandhi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R41-3-20210213","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/FPC.0000000000000034","article-title":"Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202","volume":"24","author":"Johnson","year":"2014","journal-title":"Pharmacogenet Genom"},{"key":"R42-3-20210213","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1126\/science.1195271","article-title":"The major genetic determinants of HIV-1 control affect HLA class I peptide presentation","volume":"330","author":"Pereyra","year":"2010","journal-title":"Science"},{"key":"R43-3-20210213","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet"},{"key":"R45-3-20210213","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature09534","article-title":"A map of human genome variation from population-scale sequencing","volume":"467","author":"Abecasis","year":"2010","journal-title":"Nature"},{"key":"R47-3-20210213","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nmeth.2307","article-title":"Improved whole-chromosome phasing for disease and population genetic studies","volume":"10","author":"Delaneau","year":"2013","journal-title":"Nat Methods"},{"key":"R48-3-20210213","doi-asserted-by":"crossref","first-page":"e1000529","DOI":"10.1371\/journal.pgen.1000529","article-title":"A flexible and accurate genotype imputation method for the next generation of genome-wide association studies","volume":"5","author":"Howie","year":"2009","journal-title":"PLoS Genet"},{"key":"R49-3-20210213","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fgene.2014.00370","article-title":"Imputation and quality control steps for combining multiple genome-wide datasets","volume":"5","author":"Verma","year":"2014","journal-title":"Front Genet"},{"key":"R51-3-20210213","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.1073\/pnas.0903103106","article-title":"Potential etiologic and functional implications of genome-wide association loci for human diseases and traits","volume":"106","author":"Hindorff","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"R54-3-20210213","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng.1073","article-title":"Genome-wide association study identifies multiple loci influencing human serum metabolite levels","volume":"44","author":"Kettunen","year":"2012","journal-title":"Nat Genet"},{"key":"R55-3-20210213","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R56-3-20210213","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"R57-3-20210213","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ng.2606","article-title":"Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture","volume":"45","author":"Berndt","year":"2013","journal-title":"Nat Genet"},{"key":"R58-3-20210213","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1752-8062.2012.00446.x","article-title":"High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE","volume":"5","author":"Rasmussen-Torvik","year":"2012","journal-title":"Clin Transl Sci"},{"key":"R59-3-20210213","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jmedgenet-2012-101461","article-title":"Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci","volume":"50","author":"Weissglas-Volkov","year":"2013","journal-title":"J Med Genet"},{"key":"R60-3-20210213","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng.361","article-title":"Genome-wide association study identifies eight loci associated with blood pressure","volume":"41","author":"Newton-Cheh","year":"2009","journal-title":"Nat Genet"},{"key":"R61-3-20210213","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/hmg\/ddr587","article-title":"A genome-wide association and gene\u2013environment interaction study for serum triglycerides levels in a healthy Chinese male population","volume":"21","author":"Tan","year":"2012","journal-title":"Hum Mol Genet"},{"key":"R62-3-20210213","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ajhg.2013.04.025","article-title":"Genome-wide characterization of shared and distinct genetic components that influence blood lipid levels in ethnically diverse human populations","volume":"92","author":"Coram","year":"2013","journal-title":"Am J Hum Genet"},{"key":"R63-3-20210213","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/db10-1011","article-title":"A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium","volume":"60","author":"Kraja","year":"2011","journal-title":"Diabetes"},{"key":"R64-3-20210213","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ng.2007.61","article-title":"Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides","volume":"40","author":"Kooner","year":"2008","journal-title":"Nat Genet"},{"key":"R65-3-20210213","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/FPC.0000000000000050","article-title":"Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension","volume":"24","author":"Luo","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"R66-3-20210213","doi-asserted-by":"crossref","first-page":"e91261","DOI":"10.1371\/journal.pone.0091261","article-title":"Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia","volume":"9","author":"Lopez-Lopez","year":"2014","journal-title":"PLoS One"},{"key":"R67-3-20210213","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/CIRCGENETICS.110.958728","article-title":"A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease","volume":"4","author":"Wild","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"R68-3-20210213","doi-asserted-by":"crossref","first-page":"e33389","DOI":"10.1371\/journal.pone.0033389","article-title":"Common variants in CDKN2B-AS1 associated with optic-nerve vulnerability of glaucoma identified by genome-wide association studies in Japanese","volume":"7","author":"Nakano","year":"2012","journal-title":"PLoS One"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:23:43Z","timestamp":1620951823000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201703000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000263","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}